VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. The companies reported that in early in vitro studies, an AOC candidate combining their technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of the approach to selectively deliver therapeutic oligonucleotides to disease-specific cells.
This collaboration is particularly significant as it showcases VERAXA's proprietary click chemistry-powered conjugation technology extending beyond its primary focus on solid tumors. The positive results indicate that the technology could be applied to a broader range of diseases, potentially opening new therapeutic avenues for patients with autoimmune and chronic immune conditions.
The companies are currently discussing next steps in the collaboration, which could lead to further development and eventual clinical trials. The successful application of AOCs in these disease areas could represent a major advancement in targeted therapies, offering more precise treatment options with potentially fewer side effects compared to conventional approaches.
For more details, the full press release is available at https://ibn.fm/IF9Cy.
VERAXA Biotech is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company leverages a suite of transformative technologies and rigorous quality-by-design principles to advance its pipeline. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
The latest news and updates relating to VERAXA Biotech are available in the company’s newsroom at http://ibn.fm/VRXA.
This collaboration between VERAXA and Secarna could have significant implications for the biotech industry, particularly in the field of targeted therapeutics. By combining antibody targeting with oligonucleotide therapeutics, the approach aims to deliver drugs specifically to disease-causing cells, potentially improving efficacy and reducing off-target effects. The early positive results are a promising sign for the future of AOC-based treatments.
As the companies move forward, the outcomes of this collaboration will be closely watched by researchers, investors, and patients alike. If successful, this technology could lead to new treatment options for a range of chronic immune conditions, addressing significant unmet medical needs.
For more information about BioMedWire and its services, visit https://www.BioMedWire.com.
